This agreement is an expansion of the existing partnership between both the parties focused on developing a new type of PET ligand to enhance brain-imaging.
As part of the agreement, Department of Public Health and Caring Sciences, Molecular Geriatrics at the university will focus on developing technologies for antibody-based diagnostic imaging of the brain, termed as positron emission tomography (PET), in Alzheimer patients.
BioArctic CEO Gunilla Osswald said: “We look forward to continuing the research collaboration with Uppsala University regarding new PET ligands based on our antibodies.
“This initiative is of importance to the entire field of Alzheimer research. We hope that the results will contribute to improved diagnosis of Alzheimer patients in the future and thus to a more effective treatment.”
Alzheimer’s disease is currently diagnosed through clinical examinations, measurement of biochemical markers in spinal fluid and imaging of the brain.
The disease is caused by death of neurons in the brain causing a progressive deterioration of memory and cognitive skills, including intellectual ability, language, orientation, recognition and learning ability.
In addition, the research aims to offer an enhanced method in the diagnosis of Alzheimer’s disease as well as to evaluate the effect of pharmacological treatment in the long run.
Established in 2003, BioArctic offers disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.